ABBV · Full Picture

AbbVie Inc. — the full picture

Earnings window · 2026-08-03 to 2026-11-09 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Immunology Product Demand and Expansion · UnclassifiedPriority 92
    +30.0% revenue; 4 sources (news, press_release, sec_filing, transcript); 7 forward row(s); quote_verified
    AbbVie expects Skyrizi and Rinvoq to generate $6 billion of combined growth in 2026 despite increased competition.
  2. Revenue Performance and Mix · Revenue growth & mixPriority 91
    +45.7% revenue (realized); 4 sources (news, press_release, sec_filing, transcript); 4 forward row(s); structured_verified
    AbbVie Inc. reported second-quarter adjusted EPS of $3.65 and revenue of $16.99 billion, representing 10.2% year-over-year growth.
  3. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 86
    -9.8% liability; 4 sources (news, press_release, sec_filing, transcript); 15 forward row(s); structured_verified
    Subsequent to June 30, 2026, in connection with the proposed acquisition of Apogee, AbbVie entered into a $10.0 billion 364-day senior unsecured term loan facility; no amounts had been drawn as of the date of filing of this 10-Q.
  4. Guidance / Outlook · Guidance & outlookPriority 84
    -6.3% operating_income; 4 sources (news, press_release, sec_filing, transcript); 13 forward row(s); quote_verified
    AbbVie revised its third-quarter 2026 adjusted earnings-per-share outlook to USD 3.73-3.77, down from USD 13.87-14.07.
  5. Outstanding Indebtedness · Debt, leverage & refinancingPriority 84
    -10.5% liability; 2 sources (news, sec_filing); 6 forward row(s); structured_verified
    AbbVie completed an $8.75 billion underwritten notes offering to finance a portion of its acquisition of Apogee Therapeutics.
  6. U.S. Manufacturing Investment · UnclassifiedPriority 82
    -57.5% cash; 5 forward row(s); quote_verified
    AbbVie pledged $100 billion in U.S.-based research and development and capital investments, including manufacturing, over the next decade as part of a voluntary agreement announced in January 2026.
  7. Product Launch and Transition · Products & launchesPriority 81
    +15.9% revenue; 3 sources (news, press_release, transcript); 3 forward row(s); quote_verified
    AbbVie projects its Parkinson's franchise to reach $5 billion in peak sales driven by Juvmo and other therapies like Vyalev.
  8. Operating Income and Margins · Operating income & profitabilityPriority 80
    +25.7% operating_income (realized); 3 sources (news, press_release, transcript); quote_verified
    Third-quarter 2026 operating earnings were $6.267 billion, compared with $1.904 billion in Q3 2025.
  9. Operating Expense Trends · Operating expenses (SG&A)Priority 79
    -31.8% operating_income (realized); 3 sources (press_release, sec_filing, transcript); quote_verified
    Third-quarter 2026 GAAP SG&A expense was 23.5% of net revenues, and adjusted SG&A expense was 21.2% of net revenues.
  10. Cash Flow and Capital Allocation · UnclassifiedPriority 75
    -8.3% cash (realized); 3 sources (news, sec_filing, transcript); 3 forward row(s); structured_verified
    AbbVie repurchased 5 million shares for $1.1 billion in the nine months ended September 30, 2026, compared with 3 million shares for $606 million in the same 2025 period.
  11. Competition and Market Position · Competition & market sharePriority 69
    +10.2% revenue (realized); 2 sources (news, transcript); 1 forward row(s); quote_verified
    MarketBeat projects AbbVie's Q3 2026 revenue at USD 17.34 billion, an increase from Q2's USD 16.99 billion.
  12. Drug Pricing and Tariff Relief · Tariffs & trade policyPriority 68
    2 sources (news, sec_filing); 3 forward row(s); quote_verified
    In January 2026, AbbVie agreed with the U.S. government to provide low prices in Medicaid and expand affordable direct-to-patient offerings; the government agreed to a three-year exemption for AbbVie from tariffs and future price mandates.

Threads by pillar

Revenue & Demand Priority 96 · 8 threads

Costs & Margins Priority 91 · 6 threads

Capital & Balance Sheet Priority 90 · 4 threads

Strategy & Portfolio Priority 89 · 5 threads

Legal, Regulatory & Policy Priority 87 · 8 threads

Guidance & Outlook Priority 84 · 1 thread

Macro & Market Conditions Priority 73 · 3 threads

Unclassified Priority 98 · 5 threads

Expected impact by metric

metricforward netforward grossrealized
cash-47.9%+81.5%+0.7%
revenue+51.9%+51.9%+66.7%
liability-21.4%+22.4%-12.7%
operating_income-6.3%+6.3%-9.9%
assets+0.0%+0.0%—
margin——+22.1%
net_income——-27.0%